Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of FAB122 in amyotrophic lateral sclerosis
NL-OMON53712Phase 3Completed
- Sponsor
- Ferrer
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of edaravone in amyotrophic lateral sclerosis (ALS), sponsored by Ferrer. Primary endpoint: Treatment-emergent adverse events. Started Apr 2023; status: completed.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON53712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53712.